Valneva cuts full-year outlook on lower COVID-19 vaccine sales
French vaccine developer Valneva on Thursday cut its full-year revenue outlook citing lower demand for its anti-COVID shot from European Union member states.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
Walgreens prescriptions added to San Francisco’s opioid epidemic – judge
/in TherapeuticsWalgreens Boots Alliance contributed to the opioid epidemic in San Francisco through its sale of prescription drugs in the city, a federal judge concluded on Wednesday.
Cure Rare Disease scores IND for first-in-human CRISPR therapeutic
/in R&D, TherapeuticsThe nonprofit biotech Cure Rare Disease (CRD) is headed to the clinic with a CRISPR therapeutic aimed at halting the progression of Duchenne muscular dystrophy in single-patient dosing.
BMS bets up to $1.9 billion on GentiBio’s Treg platform for IBD
/in R&D, TherapeuticsWithin the next eight years, more than 3.5 million people in the United States are expected to be diagnosed with inflammatory bowel disease. With those rising numbers in mind, Bristol Myers Squibb is doubling down on treating the condition with a nearly $2 billion partnership with GentiBio to develop Treg therapies for patients with IBD.
Merck’s blockbuster diabetes drug found contaminated with potential carcinogen
/in TherapeuticsThe FDA will still allow continued distribution of sitagliptin containing NTTP with an acceptable intake limit of 37 ng per day and up to 246.7 ng per day.
FDA Authorizes Emergency Use of JYNNEOS Vaccine for those at high risk for monkeypox infection
/in FDA/Regulatory, TherapeuticsJYNNEOS is administered beneath the skin (subcutaneously) as two doses, four weeks (28 days) apart. For individuals 18 years of age and older determined to be at high risk of monkeypox infection, the EUA now allows for a fraction of the JYNNEOS dose to be administered between the layers of the skin (intradermally).
MIT makes possible breakthrough in enabling implantable insulin device
/in R&DResearch engineers from the Massachusetts Institute of Technology have found a way to prevent scar tissue from disabling implantable devices. If established as safe and effective in humans, this technology could prove transformative in treating many diseases, such as diabetes.
Polio spreading in London, booster campaign launched for under-10s – health agency
/in TherapeuticsBritain is launching a polio vaccine booster campaign for children in London aged below 10, after confirming that the virus is spreading in the capital for the first time since the 1980s.
Abortion debate complicates the data privacy issue
/in August 2022, Issue Archives, Marketing & Advertising, TherapeuticsFederal regulation of data privacy and security has been on the back burner for the past two years, but key members of Congress have been working behind the scenes to frame bipartisan legislation and the FTC is gearing up. The Supreme Court’s decision overturning Roe v. Wade may put this issue front and center in Congress after the midterms.
Rotavirus childhood vaccine shortage hits four African countries
/in TherapeuticsSupplies of a vaccine to prevent the deadly rotavirus infection in children have either run out in Kenya, Tanzania, Senegal and Cameroon or are close to doing so, officials close to the roll-out told Reuters, after disruptions at drugmaker GSK.
